Monod Bio specializes in the development of advanced biosensors for the detection of proteins, toxins, antibodies, and various other analytes. The company utilizes a cutting-edge platform that integrates binding, transduction, and amplification processes into a single step, allowing for the efficient identification of a diverse array of target molecules. This technology enables the healthcare sector to leverage biosensors for applications in biotechnology and medicine, thereby enhancing diagnostic capabilities and improving patient outcomes.
Terray Therapeutics, Inc. operates as a biotechnology company. The company develops treatments for intractable cause of human diseases. It engages in development of a screening platform for drug discovery and Platinum Technology, which is working on an electrode-like product for deep brain stimulation. The company was founded in 2018 and is based in Pasadena, California.
HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Inspire is a patient engagement platform founded in 2005 and headquartered in Arlington, Virginia. The platform facilitates safe, permission-based connections between patients and caregivers, fostering a vital community that enhances the understanding of the patient journey. Through its online website and mobile application, Inspire allows members to compare health experiences and access a wealth of content. This rich environment provides pharmaceutical companies with integrated patient-connected longitudinal real-world data, which is essential for advancing research and improving product life cycles. By prioritizing patient engagement, Inspire plays a significant role in driving breakthroughs in healthcare.
Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.
Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.
NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.
AGERpoint, Inc. specializes in information management solutions for growers of tree and vine crops, as well as for insurers and investors. The company develops technologies that enhance data acquisition, analysis, and translation, utilizing techniques such as LiDAR to deliver precise agricultural data. AGERpoint's key products include AGERmetrix, a crop data and analytics platform, GroveTracker, which provides essential geographical and phenotypical data, VitalityTracker, which employs multispectral imaging for detailed plant analysis, and YieldTracker, which monitors harvests on a row-by-row basis. Founded in 2012 and headquartered in New Smyrna Beach, Florida, AGERpoint aims to equip growers with critical insights into their crops to optimize management and productivity.
Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
It was founded in 2018 and headquartered in Seattle, Washington.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. The company specializes in producing performance materials derived from microalgae, leveraging advancements in biology, chemistry, and materials science. Checkerspot's innovative technology platform enables the design of new materials at the molecular level, allowing for the creation of tailored solutions for various industrial applications. By integrating molecular foundry techniques with fermentation processes, the company develops sustainable materials, including polyurethanes and textile finishes, that meet the specific needs of product designers. Checkerspot collaborates closely with product users and socially responsible corporations to prototype and iterate on products, ultimately bringing superior materials to market that promote sustainability and enhanced performance.
Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.
Impact Vitals is a company focused on enhancing healthcare through the development of innovative monitoring solutions. Its flagship product, the Compensatory Reserve Index (CRI), is a non-invasive vital sign monitor that assesses changes in intravascular volume, offering early insights into a patient's tolerance to volume loss. This capability is particularly critical as traditional vital signs often fail to detect significant changes until a patient is in a state of cardiovascular collapse. By providing timely data, CRI allows for proactive interventions that can improve patient outcomes, reduce healthcare costs, and ultimately save lives. The company is currently in the early stages of commercialization, with two FDA-cleared devices already available, reflecting its commitment to advancing the field of human performance and healthcare. Incorporated in 2011 and based in Boulder, Colorado, Impact Vitals aims to leverage its technology to address vital sign monitoring challenges across various medical applications.
Phase Genomics, Inc. is a biotechnology company founded in 2015 and located in Seattle, Washington. The company specializes in advanced genomic technologies, particularly ProxiMeta Hi-C genome assembly and metagenome deconvolution. Its mission is to assist scientists in making significant discoveries by delivering highly complete and accurate genomes and metagenomes. Through its innovative approaches, Phase Genomics aims to enhance the understanding of complex biological systems, facilitating research in various fields of life sciences.
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.
Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. The company specializes in producing performance materials derived from microalgae, leveraging advancements in biology, chemistry, and materials science. Checkerspot's innovative technology platform enables the design of new materials at the molecular level, allowing for the creation of tailored solutions for various industrial applications. By integrating molecular foundry techniques with fermentation processes, the company develops sustainable materials, including polyurethanes and textile finishes, that meet the specific needs of product designers. Checkerspot collaborates closely with product users and socially responsible corporations to prototype and iterate on products, ultimately bringing superior materials to market that promote sustainability and enhanced performance.
Ant Group Co., Ltd. is a leading provider of digital payments and financial services in China, primarily known for its flagship platform, Alipay. Founded in 2000 and headquartered in Hangzhou, Ant Group offers a range of financial products, including Yu'e Bao for cash management, Huabei for consumer credit, and Xiang Hu Bao, which provides health coverage for critical illnesses. The company also operates MYbank, an online bank catering to small and micro enterprises, and Zhima Credit, an independent credit assessment service. Ant Group aims to support the digital transformation of the service industry by ensuring equal access to inclusive and sustainable financial services for consumers and small businesses. With a strong emphasis on technology and innovation, the company has played a pivotal role in enhancing trust in online transactions and has expanded its offerings to facilitate digital finance across various sectors.
Neoleukin Corporation is a biopharmaceutical company based in Seattle, Washington, that specializes in developing immunotherapies through innovative protein design technology. Originally known as Neoleukin Therapeutics, the company emerged from the University of Washington Institute for Protein Design in early 2019. It focuses on creating next-generation therapies inspired by natural protein complexes, utilizing computational methods to engineer proteins with enhanced pharmaceutical properties. The company's lead product candidate, NL-201, is a de novo protein designed to mimic the therapeutic effects of interleukin-2 and interleukin-15, targeting various cancers such as renal cell carcinoma and melanoma, as well as inflammatory and autoimmune disorders. Neoleukin Corporation operates as a subsidiary of Aquinox Pharmaceuticals, Inc., following its acquisition and subsequent rebranding.
Forterra is a non-profit organization that supports the Pacific Northwest and its wild mountains, rich ecosystems, farmland, small towns, and thriving cities.
PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutic products specifically for celiac disease. Founded in 2015, the company is working on an oral enzyme designed to break down gluten's immuno-reactive components in the stomach. This therapeutic approach aims to alleviate the painful symptoms and intestinal damage that occur from accidental gluten ingestion, thereby improving the quality of life for individuals living with celiac disease. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited, reflecting its commitment to advancing innovative solutions in the field of gastrointestinal health.
Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.
PoliarisProject is a humanitarian organization that aims to combat human trafficking and modern-day slavery. The organization operates hotlines, policy advocacy programs, client services, advisory services, strategic initiatives, data analysis programs, and global programs to achieve its mission. PolarisProject is based in Washington, D.C.
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.
Amplio offers technology that overcomes barriers like low literacy, local languages, lack of electricity or internet, and traditional gender norms and biases that often limit access to information. With the battery-powered Amplio Talking Book, their partners can deliver hours of local language audio content.
MP Materials Corp. operates the Mountain Pass facility, the only integrated rare earth mining and processing site in North America. Founded in 2017 and headquartered in Las Vegas, Nevada, the company holds mineral rights to the Mountain Pass mine and surrounding areas, alongside intellectual property related to the processing of rare earth elements. MP Materials specializes in producing neodymium and praseodymium, which are essential components for various modern technologies. By restoring the full rare earth supply chain to the United States, the company aims to support national security, create jobs, and promote sustainable practices in the industry.
Water1st International is a non-profit organization that provides and supports piped water systems and toilets projects for the world’s poorest communities that improve health, create opportunity, and break the cycle of extreme poverty.
Uterish operates as an online platform to connect activists, sell feminist apparel, publish an informative monthly newsletter, produce and curate opinionated blog posts, and support Planned Parenthood and the right to bodily autonomy.
Earth Economics identifies and quantifies those benefits to ensure they are included in the decision-making process at all levels.
BROTMAN BATY INSTITUTE focuses on basic and applied research in genomics, bioinformatics, and data science to diagnose and cure disease. The Institute was founded in 2017 by philanthropic sponsors Jeff and Susan Brotman, and Dan and Pam Baty in collaboration with UW Medicine, The Fred Hutchinson Cancer Research Center, and Seattle Children’s. The Institute led by Dr. Jay Shendure was formed to accelerate both the basic sciences of precision medicine and the delivery of benefits to patients. The Institute organizes world-renowned investigators in genomics, bioinformatics and data science to share centralized platforms of advanced technologies and equipment in a uniquely collaborative manner. The Institute's aim is to develop insights and knowledge that will more precisely diagnose and treat people with cancer, rare childhood diseases, Alzheimer’s, and other conditions.
GIRC&D is a community-based organization focused on the prudent use of natural and human resources. Originally sponsored by the U.S. Department of Agriculture and initially administered by the Natural Resources Conservation Service—a federal agency—we are now locally managed. The organization provides many avenues for worthy projects to succeed. Some projects that GIRC&D hosts are finite, but leave a lasting impact. Others become entities and nonprofit organizations on their own. Seven committees outreach to the community; one committee functions internally.
Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent. Fred Hutchinson Cancer Research Center was incorporated in 1971 and is based in Seattle, Washington.
Owl Rock Capital is an investment management firm based in New York City, specializing in providing tailored financing solutions for middle-market companies in the United States. Founded in 2016, the firm focuses on both debt and equity investments, including senior secured and unsecured loans, subordinated loans, and mezzanine financing, as well as equity-related securities. It primarily targets companies with annual revenues ranging from $50 million to $2.5 billion and EBITDA between $10 million and $250 million. Owl Rock Capital aims to meet the unique financing needs of its clients by leveraging its expertise in various sectors, including technology, healthcare, consumer products, and business services. The firm emphasizes a one-stop financing approach, positioning itself as a desirable lending partner for middle-market companies and their sponsors.
AgeneBio, Inc. is a neuroscience pharmaceutical company founded in 2008, focused on developing therapeutic products for Alzheimer's disease, dementia, and other memory disorders. The company aims to address Amnestic Mild Cognitive Impairment and Alzheimer's disease through innovative treatments. Although headquartered in Indianapolis, AgeneBio conducts its research and development activities globally, leveraging partnerships to enhance its capabilities. The company's mission is to improve the lives of individuals affected by memory-related diseases through effective therapeutic interventions.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, specializing in innovative cell therapies for cancer treatment, particularly targeting solid tumors. The company utilizes its specific peptide enhanced affinity receptor (SPEAR) T-cell platform to identify and genetically engineer T-cell receptors that enhance the immune response against cancerous cells. Current clinical trials are exploring various therapeutic candidates, including ADP-A2M4 for multiple solid tumor types and ADP-A2AFP for hepatocellular carcinoma. Adaptimmune has formed strategic collaborations with several organizations, including GSK for the development of NY-ESO T-cell therapy and Noile-Immune Biotech Inc. for combining SPEAR T-cells with PRIME technology. Founded in 2008, Adaptimmune is committed to advancing T-cell therapies to improve patient outcomes in oncology and beyond.
The mission of the University of Washington Institute for Protein Design is to design a new world of proteins to address 21st century challenges in medicine, energy and technology. The Institute for Protein Design was established in 2012, and is building on strengths within the University of Washington and Seattle more generally. Protein design requires high-level expertise and talent in computing and software, biochemistry, genome sciences, biological structure, pharmacology, immunology and other basic science disciplines, as well as clinical medicine. They are marshaling deep institutional strengths in our faculty, scientific staff, postdoctoral fellows and graduate students, their partners from collaborating institutions, innovator networks, and from the computer and biotechnology industries — bringing extraordinary expertise to bear on a singular focus to advance the potential of protein design. Over the past 16 years, UW researchers have made significant progress in protein design and protein structure prediction, developing the world leading Rosetta software. During this period, UW scientists have developed methods for designing proteins with a wide range of new functions, including catalysts for chemical reactions, HIV and RSV vaccine candidates, and flu virus inhibitors. The IPD integrates these strengths in protein design with Seattle-area expertise in biochemistry, engineering, computer science and medicine, and leverages the exceptional Seattle strength in the software industry.
Washington Environmental Council is a non profit organisation that specializes in protect, restore, and sustain Washington’s environment.
Context Logic provides a tool to promote relevant content on websites. It offers a native advertising platform for advertisers to display their ads that match the form and context of the website. The technology uses machine learning and NLP to leverage information context in order to increase the relevancy of advertising. Its algorithm uses a topic hierarchy to break down what people actually are looking for or find interesting.
Private Equity Round in 2011
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
OCEAN FUTURES SOCIETY works to explore our global ocean, inspiring and educating people throughout the world to act responsibly for its protection, documenting the critical connection between humanity and nature, and celebrating the ocean's vital importance to the survival of all life on our planet.
Plymouth Housing’s mission is to eliminate homelessness and address its causes by preserving.
Amara is an individual and family services organization that drives systemic change, promotes healing, racial, and LGBTQIA+ equity, by offering programs and services to families engaged in foster care, and to adoptees and families, post-adoption.
Institute for Stem Cell and Regenerative Medicine (ISCRM) was founded in 2006 at the University of Washington by Tony Blau, Randy Moon, and Chuck Murry. The Institute is working to transform therapies for heart failure, neurodegenerative diseases including Parkinson’s and Alzheimer’s, muscular dystrophy, cancer, diabetes, hearing loss, and retinal, kidney, and liver diseases. Our scientists are conducting research using multiple approaches including pluripotent stem cell technology, gene therapy and precision medicine with the goal of developing novel therapies for diseases where there are few treatments at present.
Imagine a world where people are healthy. There would be less poverty and fewer orphans. There would be stronger economies. There would be hope.Seattle Biomedical Research Institute (Seattle BioMed) was founded at a time when infectious disease research in the U.S. was rare. Our founder had a vision to create a place where the brightest scientists could come together and generate new knowledge and develop innovative solutions to ultimately combat the world’s deadliest diseases. Today that vision is reality. 360 people strong, we're an internationally renowned, non-profit research Institute striving every day to eliminate the world's most devastating infectious disease.
R Baby is the first and only foundation focused on making sure every emergency room is prepared to give babies and children lifesaving care. The organization focuses on the delivery optimal pediatric emergency training, research, treatment, and equipment.
Ashesi University is a private, non-profit liberal arts institution located in Ghana, dedicated to educating ethical and entrepreneurial leaders. Established in March 2002 with a pioneering class of 30 students, the university has rapidly gained recognition for its innovative and high-quality education. Ashesi integrates a liberal arts core curriculum with specialized majors in fields such as computer science, business administration, management information systems, and engineering disciplines. The university aims to cultivate critical thinking skills, a sense of social responsibility, and the courage necessary for students to drive transformation across Africa. Through its commitment to raising the standards of higher education in the region, Ashesi aspires to contribute significantly to a renaissance in Africa.
The Center for Constitutional Rights is dedicated to advancing and protecting the rights guaranteed by the United States Constitution and the Universal Declaration of Human Rights. Founded in 1966 by attorneys who represented civil rights movements in the South, CCR is a non-profit legal and educational organization committed to the creative use of law as a positive force for social change.
The Dian Fossey Gorilla Fund is a non-profit organization dedicated to gorilla conservation.
Brady works across Congress, courts, and communities to end gun violence.
As the political leader of the pro-choice movement, NARAL Pro-Choice America marshals its resources—the power of people, policy expertise, and political acumen—to make a difference in the lives of women and their families.With more than one million members and supporters, NARAL Pro-Choice America uses the political process to guarantee every woman the right to make personal decisions regarding the full range of reproductive choices, including preventing unintended pregnancy, bearing healthy children, and choosing legal abortion.We are working with the Obama administration and Congress to pursue commonsense solutions, like increasing access to family planning and sex education, and reversing President Bush's anti-choice legacy.
PESTICIDE ACTION NETWORK NORTH AMERICA is a biotech corporations company provides environment and agriculture into international network.
Queens College offers a rigorous education in the liberal arts and sciences under the guidance of a faculty dedicated to both teaching and research. Students graduate with the ability to think critically, address complex problems, explore various cultures, and use modern technologies and information resources.
PACIFIC WILDLIFE PROJECT is a humane organization specializing in the rescue and care of wildlife. PACIFIC WILDLIFE PROJECT was Founded in 1985 with the humane goal of wildlife protection and preservation through education, community outreach, and rescue and medical treatment of all wild species.
Northwest Harvest distributes food to a network of more than 370 food banks, meal programs, and high-need schools throughout Washington State.
Galapagos Conservancy is dedicated exclusively to the long-term protection of nature. Galapagos Conservancy is committed to strengthening local institutions and to creating local capacity to ensure the long-term protection of the archipelago.